IRIX IRIDEX CORP
Price Chart
Executive Summary
IRIDEX reported Q1 2026 revenue of $11.8M, down 1% YoY, while net loss improved to $0.5M from $1.7M. The company reaffirmed FY2026 revenue guidance of $51M-$53M and expects positive operating cash flow. Retina sales declined due to supply constraints, partially offset by Cyclo G6 glaucoma probe growth of 14%.
Key Financial Metrics
Actionable Insight
Revenue decline and reaffirmed guidance suggest near-term stability but no catalyst. Watch for retina sales recovery in subsequent quarters and cash flow generation per management's positive full-year outlook.
Key Facts
- Q1 2026 revenue $11.8M vs $11.9M YoY (-1%)
- Net loss $0.5M ($0.03/share) vs $1.7M ($0.10/share) YoY
- Gross margin 40% vs 43% YoY due to tariffs and manufacturing costs
- Cyclo G6 product revenue grew 14% to $3.6M; retina revenue fell 12% to $5.8M
- FY2026 revenue guidance reaffirmed at $51M-$53M; expects positive operating cash flow
- Cash decreased $1.4M to $4.6M, primarily due to normal Q1 compensation timing
Financial Impact
Revenue $11.8M (-1% YoY); net loss improved to $0.5M from $1.7M; adjusted EBITDA $0.3M vs $0.4M
Risk Factors
- International supply constraints and delayed regulatory approvals weighing on retina sales
- Tariff impact on gross margins (40% vs 43% YoY)
- Cash burn of $1.4M in Q1; full-year positivity depends on execution
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-230774 |
| Document: irix-20260519.htm | 0001193125-26-230774 |
| Document: 0001193125-26-230774-index-headers.html | 0001193125-26-230774 |
| Document: 0001193125-26-230774-index.html | 0001193125-26-230774 |
| Document: 0001193125-26-230774.txt | 0001193125-26-230774 |
| 8-K Data (Synthetic) | 0001193125-26-230774 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 19, 2026
26d ago
|
8-K
| $1.00 $1.03 | ▲ +3.00% | ▲ +1.76% | $1.12 (+12.00%) |
|
Apr 24, 2026
7w ago
|
DEFA14A
| $1.08 $1.09 | ▲ +0.93% | ▲ +0.53% | $1.12 (+3.70%) |
|
Apr 7, 2026
9w ago
|
Press Release
| $1.03 $1.04 | ▲ +0.97% | ▼ −2.55% | $1.12 (+8.74%) |
|
Mar 26, 2026
11w ago
|
Press Release
| $0.9900 $1.00 | ▲ +1.01% | ▼ −2.85% | $1.12 (+13.13%) |
|
Mar 12, 2026
13w ago
|
Press Release
| $1.30 $1.35 | ▲ +3.85% | ▲ +5.96% | $1.12 (−13.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access